Journal
PHARMACOLOGICAL RESEARCH
Volume 165, Issue -, Pages -Publisher
ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
DOI: 10.1016/j.phrs.2021.105467
Keywords
Cardiovascular disease; Protein O-GlcNAcylation; O-GlcNAc transferase; O-GlcNAcase
Categories
Funding
- Hull and East Riding Cardiac Trust Fund
- Tertiary Education Trust Fund (Tetfund), Nigeria [TETF/ES/UNIV/EDO STATE/TSAS/2019/VOL.1]
- University of Benin, Nigeria
Ask authors/readers for more resources
Protein O-GlcNAcylation has emerged as a new mechanism in the pathogenesis of cardiovascular diseases, playing a vital role in modulating vascular homeostasis and cardiac function through altering cellular functions of target proteins. Studying this mechanism may provide new therapeutic targets for the development of more effective medicines.
Cardiovascular diseases (CVDs) are the leading cause of death globally. While the major focus of pharmacological and non-pharmacological interventions has been on targeting disease pathophysiology and limiting predisposing factors, our understanding of the cellular and molecular mechanisms underlying the pathogenesis of CVDs remains incomplete. One mechanism that has recently emerged is protein O-GlcNAcylation. This is a dynamic, site-specific reversible post-translational modification of serine and threonine residues on target proteins and is controlled by two enzymes: O-linked beta-N-acetylglucosamine transferase (OGT) and O-linked beta-N-acetylglucosaminidase (OGA). Protein O-GlcNAcylation alters the cellular functions of these target proteins which play vital roles in pathways that modulate vascular homeostasis and cardiac function. Through this review, we aim to give insights on the role of protein O-GlcNAcylation in cardiovascular diseases and identify potential therapeutic targets in this pathway for development of more effective medicines to improve patient outcomes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available